Navigation Links
EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease
Date:7/14/2010

ent it is close to concluding the pre-clinical development process and hopes to begin clinical trials in 2011.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia.  The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and is currently in Phase IIb clinical trials for cognition disorders in Alzheimer's disease and schizophrenia.  The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule which is in preparation for Phase II studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
2. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
(Date:9/18/2014)... , Sept. 18, 2014 Just days before ... a three-day quarantine to contain the spread of Ebola, World ... medical relief supplies – thanks to private donations. ... United States , through its affiliate McKesson Medical-Surgical donated ... the entire country of Sierra Leone,s ...
(Date:9/17/2014)... Sept. 17, 2014 North America Gynecological ... GlobalData,s new report, "North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3
... Bias, DURHAM, N.C., Sept. 15 Less ... treatment are eventually published in,medical journals, according to ... Oncologist.", (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), ... of Washington and,Fred Hutchinson Cancer Research Center, Seattle, ...
... a novel ... macrolide-related drug class, WATERTOWN, Mass., Sept. ... molecule anti-infective drugs, announced,today the initiation of a Phase 1 ... novel,macrolide-related drug class with a distinct resistance profile. The,clinical development ...
Cached Medicine Technology:Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 2Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA 3
(Date:9/18/2014)... York and London. (PRWEB) September 18, 2014 ... of Computer Aided Engineering software, today announced its new ... will be utilizing the CD-adapco simulation tool, STAR-CCM+® in ... team just announced its participation in the 35th America’s ... the 35th edition of the America’s Cup is sustainability, ...
(Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
(Date:9/18/2014)... in German . ... have won the ,International Space Station Research Competition, with ... prize, the scientists will see the International Space Station ... involves crystallizing two proteins of the hepatitis C virus ... the International Space Station is scheduled to lift off ...
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... According to a new market report published by ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - ... at USD 77607.7 million in 2013 and is expected to ... to reach an estimated value of USD 115474.9 million in ... growing at a rapid pace due to increasing prevalence of ...
Breaking Medicine News(10 mins):Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2Health News:Hepatitis C virus proteins in space 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4
... preventing medical support staff from completing orders for outpatient ... in a marked decrease in low-yield exams for patients, ... of Radiology . Many medical institutions request ... web-based radiology order entry systems. Some systems offer real-time ...
... and acceptance Three new reports describe biomarkers ... excellent and stable allograft function in the absence of ... transplants. Peter Heeger and Bernd Schrppel, at Mount Sinai ... commentary, the importance of these studies and how they ...
... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ...
... predisposition to delivering early, , MONDAY, May 24 (HealthDay News) ... to give birth to a baby who isn,t full-term, a ... who weren,t born early but had one or more siblings ... researchers. , "There was a suspicion that preterm birth might ...
... To prevent rejection of their new kidneys, kidney transplant recipients ... lives. A handful of people, out of the thousands who ... drugs without losing their kidneys. Researchers studying these rare ... their white blood cells, which may one day be used ...
... kids with blood sugar disease , MONDAY, May 24 (HealthDay ... enteroviruses -- which can cause viral meningitis -- and diagnoses ... how the two might be linked, but the findings suggest ... for diabetes in its early stages, lead researcher Antonio Toniolo, ...
Cached Medicine News:Health News:Simple change results in fewer unnecessary imaging exams for patients 2Health News:JCI table of contents: May 24, 2010 2Health News:JCI table of contents: May 24, 2010 3Health News:JCI table of contents: May 24, 2010 4Health News:JCI table of contents: May 24, 2010 5Health News:JCI table of contents: May 24, 2010 6Health News:JCI table of contents: May 24, 2010 7Health News:JCI table of contents: May 24, 2010 8Health News:JCI table of contents: May 24, 2010 9Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 2Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 3Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 4Health News:Women Born Early More Apt to Have Preterm Baby 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Viral Infection Could Be Marker for Type 1 Diabetes 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: